SIRT1 and Huntington disease: Indeed, two independent studies by our group (Jiang et al., 2011) and Krainc’s group (Jeong et al., 2011) demonstrated that modulating the levels of SIRT1 has therapeutic benefit in three different HD mouse models, and putative downstream targets of SIRT1 involved in improved disease outcomes are also identified.